Trial Profile
Effect of palivizumab on respiratory syncytial virus-associated burden of disease: a randomised controlled trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections; Wheezing
- Focus Proof of concept; Therapeutic Use
- Acronyms MAKI
- 01 Dec 2021 Results assessing the effects of early life RSV prophylaxis on having RSV infection and asthma symptoms in the first years of life and performed an EWAS to identify differentially methylated patterns in relation to palivizumab prevention at the global, individual, and regional CpG site level, published in the Pediatric Pulmonology.
- 09 May 2013 Status changed from recruiting to completed.
- 09 May 2013 Results published in the New England Journal of Medicine.